News

Psilocybin: A New Horizon in the Treatment of Depression

By Gabriel García in News

September 16, 2024

In an effort to find alternatives to traditional treatments for depression, a recent study has put the spotlight on psilocybin, a psychedelic compound found in hallucinogenic mushrooms. Published in the medical journal BMJ, the study compared the efficacy of psilocybin with that of escitalopram, a selective serotonin reuptake inhibitor (SSRI) and one of the most commonly prescribed antidepressants. The Promise of Psychedelics SSRIs, such as escitalopram, have been a mainstay in the treatment of depression for decades.

More information

Experts Warn of Ayahuasca's Extinction

By Gabriel García in News

September 9, 2024

Ancestral medicine teachers from the Shipibo nation of Peru recently gathered for an urgent meeting to address the effects of spiritual tourism and corporate exploitation, issues that put their sacred medicine and territory at risk. An Urgent Meeting to Protect Ayahuasca In July 2024, more than one hundred Onanyabo, or Shipibo-Conibo ancestral medicine healers from the Ucayali region of Peru, gathered at the Instituto Superior Pedagógico Bilingüe de Yarinacocha.

More information

New Psychedelic Mushroom Species Discovered in Africa

By Gabriel García in News

September 2, 2024

In a finding that underscores the undiscovered biological richness of the African continent, two new species of psychedelic mushrooms have been identified in southern Africa. These species, both of the genus Psilocybe, known to contain psilocybin, the active psychedelic compound, were found in areas previously unexplored by Western science. Psilocybe ingeli: A Discovery in the Kwa-Zulu Mountains Psilocybe ingeli was discovered by Talan Moult, a self-taught mycologist, in the Kwa-Zulu Mountains, South Africa.

More information

New Psychedelics Medical Research Centre Opens in Kingston, Ontario

By Gabriel García in News

August 20, 2024

A new medical research centre dedicated to psychedelics has opened in Kingston, Ontario, marking a significant milestone in the study of these substances and their therapeutic potential. The Centre for Psychedelics Health and Research, launched on August 7, 2024, at Providence Care Hospital, aims to enhance ongoing work at Queen’s University and deepen understanding of the use of psychedelics in treating mental health issues. Advancing Psychedelic Research Psychedelics, substances known for causing psychological effects such as hallucinations, have been used for millennia by Indigenous peoples as healing tools.

More information

FDA Rejects MDMA for PTSD Treatment: What’s Next for Psychedelic Therapy?

By Gabriel García in News

August 12, 2024

On 9 August 2024, the US Food and Drug Administration (FDA) dealt a significant blow to the movement advocating MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD). Lykos Therapeutics, the pharmaceutical company leading the MDMA approval effort, received a “complete response letter” from the FDA, indicating that the agency will not approve the treatment until further research is conducted. This decision has sent shockwaves through the psychedelic therapy advocacy community, raising questions about the future of MDMA and other psychedelic treatments.

More information

The Potential Benefits of Psychedelics on Brain Health: A Recent Study

By Gabriel García in News

Recent research is revealing the potential benefits of psychedelics on brain health, particularly in the cognitive and emotional realms. A recent meta-analysis published in the Journal of Psychopharmacology has identified that people who use psychedelics have significantly higher levels of brain-derived neurotrophic factor (BDNF) compared to non-users. This increase in BDNF suggests that psychedelics may enhance the brain’s ability to adapt and reorganise itself, offering new opportunities to treat mental disorders.

More information

California Lawmakers Reject World's Most Modest Psychedelic Reform

By Gabriel García in News

The world’s most modest psychedelic reform bill has failed yet again in the California Legislature. The bill would have allowed three counties to establish pilot programmes in which military veterans could take psilocybin under the supervision of medical professionals. An Ambitious Bill That Failed to Come to Fruition The bill’s sponsors decided to withdraw the legislation, KQED reports. The decision was made because of the certainty of a “no” vote at an upcoming Assembly Health Committee hearing.

More information

Older People Using Psychedelics Show Fascinating Brain Functions

By Gabriel García in News

Drugs with psychedelic effects, such as psilocybin, LSD, MDMA and cannabis, may help protect the brain from some aspects of ageing, a new study suggests.The survey, which included 3,294 US adults aged 42 to 92, found that those who reported using some type of hallucinogen in the past year showed fewer depressive symptoms and improvements in higher-order brain function. Key Study Findings Users of psychedelics scored higher on telephone tests assessing inductive reasoning, verbal fluency, working memory, processing speed, attentional switching and inhibitory control.

More information

Study Reveals Mushrooms Are the Most Used Psychedelic Substance in the U.S.

By Gabriel García in News

A recent RAND report has revealed that mushrooms, also known as psilocybin, are the most widely used psychedelic drug in the United States. This finding provides detailed insight into the use of psychedelics among Americans and may guide policymakers in regulating these substances for mental health treatment or even legalising them for recreational use. Importance of the Study Understanding how and how much psychedelics are used in society is crucial for policymakers, especially at a time when new forms of regulation are being discussed.

More information

Ketamine in Tablet Form for Depression: New Method Demonstrates Efficacy

By Gabriel García in News

A recent phase 2 clinical trial has demonstrated the safety and efficacy of extended-release ketamine tablets for patients with depression resistant to other treatments. This breakthrough promises to revolutionise the treatment of major depressive disorder (MDD), a condition that affects nearly 40 million people in Europe and is a leading cause of disability worldwide. A Persistent Problem MDD can be devastating, with a 20 times higher risk of suicide compared to the general population.

More information

Why closing your eyes makes you travel more, says scientific study

By Gabriel García in News

In the ever-evolving field of psychedelic research, a groundbreaking study has recently highlighted the profound impact that closing one’s eyes can have on the intensity of a psychedelic experience. Published in the journal ACS Chemical Neuroscience, the study explores the nuances of “set and setting”, a well-known concept in the psychedelic community that emphasises the importance of mindset and environment during a trip. This study, however, is the first to provide quantitative evidence showing how these factors, particularly eye closure, can modulate the effects of psychedelics such as LSD.

More information

Natural psilocybin more effective in therapy than synthetic psilocybin, new study finds

By Gabriel García in News

Recent research reported by Double Blind Mag has uncovered significant findings that could reshape the landscape of psychedelic-assisted therapy. A study published in the journal Molecular Psychology suggests that a full-spectrum extract of psychedelic mushrooms offers more potent and prolonged therapeutic effects than isolated psilocybin, the main active compound traditionally studied in clinical settings. The study and its implications The research team, comprising experts from institutions such as the Hadassah Medical Center of the Hebrew University of Jerusalem and Boston-based Human Metabolome Technologies, focused on comparing the effects of full-spectrum psychedelic mushroom extract (PME) and chemically synthesised psilocybin (PSIL).

More information

New study says therapeutic use of psilocybin does not cause paranoia

By Gabriel García in News

Marijuana Moment has reported new research from the American Medical Association (AMA) has found that the use of psilocybin in the context of therapy significantly reduces the risk of long-lasting adverse effects. The study, published in JAMA Psychiatry in April, shows that the use of a single dose of psilocybin “is not associated with risk of paranoia”, and other adverse effects, such as headaches, are generally “tolerable and resolve within 48 hours”.

More information

Israel joins research on psychedelics

By Gabriel García in News

In a significant step towards researching the therapeutic effects of psychedelics, Israel has joined the international scene through a pioneering collaboration between Optimi Health Corp. and the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). This partnership marks Optimi’s foray into the Israeli psychedelic market and promises to contribute to the advancement of knowledge in the field of mental health and addiction. In this collaboration, Optimi will supply MDMA to the IPR-TLV to support research on the effects of this compound in animal models of alcohol addiction.

More information

EU funds first psychedelics project in Portugal, Netherlands, Czech Republic and Denmark

By Gabriel García in News

The European Union (EU) has taken a historic step by funding for the first time a project that uses psychedelics, such as the well-known “magic mushrooms”, to address the treatment of depression, especially in the field of palliative care and for people with various illnesses. This innovative EU-backed project marks a significant milestone in medical research and treatment of mental and physical health conditions. Psychedelics, compounds that alter consciousness, include lysergic acid diethylamide (LSD), psilocybin (found in magic mushrooms), methylenedioxymethamphetamine (MDMA or ecstasy), dimethyltryptamine (DMT) and ayahuasca, among others.

More information

Utah Psychedelics Pilot Programme: A New Frontier in Health Care

By Gabriel García in News

In a bold step towards innovative health options, Utah’s Republican governor, Spencer Cox, has allowed a groundbreaking bill authorising a pilot programme for hospitals to administer psilocybin and MDMA as alternative treatment options to become law despite his reservations. This decision is an important step forward in exploring the therapeutic potential of psychedelics and their role in mental health treatment. Cox, in a letter to legislative leaders, expressed his doubts, but ultimately relented in the face of the “overwhelming support” for the legislation, with both houses unanimously backing the measure.

More information

The Psychedelic Renaissance: A New Era in Mental Therapy

By Gabriel García in News

The world of mental health is on the verge of a revolution, thanks to a resurgence of interest in psychedelics, known as the Psychedelic Renaissance. This movement is being driven by growing scientific evidence suggesting that substances such as psilocybin, MDMA, DMT, ketamine and LSD have significant therapeutic potential for treating conditions such as depression, anxiety, post-traumatic stress disorder (PTSD) and addiction. The publisher Argonowta has recognised the importance of this phenomenon and has decided to relaunch “The Essential Guide to the Psychedelic Renaissance”, a comprehensive overview of this emerging field.

More information

Economic investment in the psychedelic industry is growing at an unprecedented rate

By Gabriel García in News

The psychedelic medicine industry is experiencing an unprecedented boom, with an avalanche of capital and fierce competition among new biotech startups. These companies are determined to commercialise drugs that are expected to revolutionise the treatment of depression, addiction and other mental illnesses. Although psychedelics remain illegal under federal law in the United States, companies are desperately seeking to patent key ingredients found in hallucinogenic mushrooms, ayahuasca and other substances used for centuries by indigenous cultures and, more recently, in clandestine contexts.

More information

Can increased use of psychedelics lead to more hospitalisations and emergency room visits?

By Gabriel García in News

In recent years, there has been a marked increase in the use of psychedelics, accompanied by a wave of decriminalisation initiatives in several cities and states. At the same time, the FDA’s gradual approval of psychedelic-assisted therapies has signalled a shift in the perception of these substances from taboo to potential therapeutic tools. However, amid this evolving landscape, concerns have been raised about the impact of increased psychedelic use on public health.

More information

The potential of psychedelics on sexual function

By Gabriel García in News

February 23, 2024

There has long been anecdotal speculation about the impact of psychedelics on sexual function, but until now, scientific evidence has been scant. However, a recent study by researchers at the Centre for Psychedelic Research at Imperial College London has shed light on this issue, showing that hallucinogenic mushrooms, LSD and other psychoactive compounds may play a role in improving sexual function, even months after the psychedelic experience. The main aim of the study was to examine the effects of psychedelics on sexual function, as well as on individual perceptions of sexual relationships, sexual exploration and spirituality.

More information

DXM, psilocybin and its potential therapeutic effects

By Gabriel García in News

February 16, 2024

In a pioneering study, researchers at Johns Hopkins Medicine have opened new doors to the treatment of depression and other psychiatric disorders by unconventional means. Their recent study, published in the prestigious journal Psychedelic Medicine, sheds light on the promising benefits of high doses of DXM (dextromethorphan) and psilocybin - substances previously relegated to the realm of recreational or taboo use - when administered in a controlled and supportive environment.

More information

California Lawmakers Propose Bill to Legalise Therapeutic Use of Psychedelic Mushrooms

By Gabriel García in News

February 9, 2024

On 9 February 2024, California lawmakers took a bold step towards the future of mental health by introducing Senate Bill (SB)1012, an initiative that could transform the state’s therapeutic landscape. Known as the “Regulated Psychedelic Assisted Therapy Act”, the bill’s main goal is to allow the therapeutic use of psychedelic mushrooms under professional supervision. Senator Scott Wiener, along with Assemblymen Josh Lowenthal and Marie Waldron, are the main drivers of this initiative, which seeks to address the shortcomings of the current mental health system in California.

More information

Breaking Barriers: Australia Leads the Way with Psychedelic Assisted Therapy

By Gabriel García in News

February 1, 2024

In a groundbreaking development, a team at Monarch Mental Health Group achieved a significant milestone in mental health treatment by conducting the world’s first Psychedelic Assisted Therapy (PAT) outside of research and compassionate use protocols. This innovative approach, utilizing MDMA, a psychedelic medicine, has demonstrated remarkable success in treating a lady with chronic treatment-resistant PTSD. The lead doctor shared the achievement on LinkedIn, expressing the profound impact of a single day of MDMA-assisted therapy, surpassing the typical progress seen in a year of traditional treatments.

More information

DEA confirms psychedelic mushroom spores are legal

By Gabriel García in News

January 26, 2024

Psychedelic mushrooms are mushrooms that contain hallucinogenic substances, such as psilocybin or psilocin, which can alter the perception, mood and thinking of those who consume them. These mushrooms have been used since ancient times by various cultures for ritual, religious or therapeutic purposes. However, in many countries, their possession, cultivation and consumption are prohibited or restricted by law. In the United States, psychedelic mushrooms are listed as Schedule I controlled substances, meaning that they are considered to have no accepted medical use and a high potential for abuse.

More information

Psychedelics may help brain damage, new study finds

By Gabriel García in News

January 19, 2024

Psychedelics are substances that alter perception and consciousness, such as LSD, psilocybin, MDMA, DMT and ayahuasca. These drugs can have beneficial effects in treating mental disorders such as depression, anxiety, post-traumatic stress disorder and addiction, but they can also have negative effects on the brain if used inappropriately or without medical supervision. According to an article published in the journal ‘New Scientist’, psychedelics can help repair brain damage caused by trauma or injury, stimulating the growth of new neurons and synapses, and facilitating the learning of new skills.

More information

Atai invests $50m in psychedelics research

By Gabriel García in News

January 12, 2024

Psychedelics are substances that alter perception, consciousness and mood, causing intense sensory experiences and sometimes hallucinations. Some of the best known psychedelics are LSD, psilocybin (found in magic mushrooms), DMT (a component of ayahuasca) and mescaline (extracted from certain cacti). These substances have been used for centuries by various indigenous cultures for ritual, spiritual and therapeutic purposes. However, their use in the West has been limited by their legal prohibition and social stigma, associating them with the hippie counterculture of the 1960s and 1970s.

More information

2023: A review of legal developments in psychedelics this year

By Gabriel García in News

January 5, 2024

The National Law Review has published an article on the legal status of psychedelics in the United States through 2023. The article, entitled “2023: A Good Trip Around the Sun for Psychedelics” and written by attorneys Michael C. Littenberg and Sarah E. Aberg of Ropes & Gray LL, reviews not only the milestones, but also the future of psychedelics. As you probably know, psychedelics are substances that alter perception, mood and thought, such as LSD, psilocybin, ayahuasca and ketamine.

More information

FDA may approve prescription of MDMA-assisted therapy for PTSD thanks to MAPS

By Gabriel García in News

December 20, 2023

A historic milestone in psychedelic research has been reached with the submission by the Multidisciplinary Association for Psychedelic Studies (MAPS) of the first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for MDMA-assisted therapy for post-traumatic stress disorder (PTSD). MDMA-assisted therapy consists of a combination of psychotherapy sessions with and without the supervised use of MDMA, a psychoactive substance that has been shown to enhance the effectiveness of psychotherapy by reducing fear and increasing confidence, empathy and introspection.

More information

How antidepressants, ketamine and psychedelic drugs can flex the brain, new research shows

By Gabriel García in News

December 13, 2023

The article “How antidepressants, ketamine and psychedelic drugs may make brains more flexible - new research” by Barbara Jacquelyn Sahakian, Professor of Clinical Neuropsychology at the University of Cambridge, and Christelle Langley, Postdoctoral Research Associate in Cognitive Neuroscience at the University of Cambridge explains how these drugs may affect brain neuroplasticity, i.e., the brain’s ability to change and adapt to new experiences. According to the authors, these drugs can help treat mental disorders such as depression, anxiety and post-traumatic stress by facilitating the formation of new neural connections and the modulation of brain circuits involved in emotional processing.

More information

You can now read the first chapters of the Psychonaut's Guides for FREE

By Gabriel García in News

December 6, 2023

Would you like to read the first chapter of the Psychonaut’s Guides from Argonowta Publishing? These books are a collection of texts that explore the world of psychedelic substances and their possible benefits for mental health. In them you will find scientific information, personal testimonials, practical advice and useful resources for those who want to learn more about these substances and their effects. Psychedelic substances are those that alter the perception, thinking and mood of the user.

More information

The forgotten story of women in the history of psychedelics

By Gabriel García in News

November 24, 2023

Women have played an important role in the history of psychedelics, whether as researchers, therapists, artists or activists. However, their contributions have often been ignored or downplayed by a patriarchal culture that has dominated the field of psychedelia. In this article, we will review some of the most relevant female figures who have explored the potential of these substances for mental health, self-knowledge and social transformation. One of the pioneers was Maria Sabina, a Mazatec healer living in the mountains of Oaxaca, Mexico.

More information

MDMA and its potential therapeutic effects.

By Gabriel García in News

November 17, 2023

MDMA, also known as ecstasy, is a psychoactive substance that has become popular as a recreational drug because of its stimulant and entactogenic effects. However, before MDMA was banned and stigmatized, some psychiatrists used it as a tool to facilitate psychotherapy, especially in cases of post-traumatic stress disorder (PTSD), anxiety and depression. What is it about MDMA that makes it potentially therapeutic? According to studies conducted with healthy volunteers, MDMA produces a series of psychological effects that can favor the therapeutic process, such as:

More information

Michael Pollan: There's a dangerous message that psychedelics will solve all your mental health problems

By Gabriel García in News

November 10, 2023

Psychedelics are substances that alter the perception, mood and thinking of the people who consume them. Some of them, such as LSD, psilocybin or ayahuasca, have been used for centuries by various cultures for ritual, religious or therapeutic purposes. However, in recent decades, these compounds have aroused renewed scientific interest for their potential to treat various mental disorders, such as depression, anxiety, post-traumatic stress or addictions. In a recent interview published in the newspaper El País, the American journalist and writer Michael Pollan, author of the book How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Death, Addiction, Depression and Transcendence (Debate, 2018), talks about his personal experience and research into the world of psychedelics.

More information

Psychedelic drugs reopen 'critical periods' for social learning, study suggests

By Gabriel García in News

November 3, 2023

Psychedelics are substances that alter perception, mood and thought, and have been used by various cultures throughout history for ritual, religious and therapeutic purposes. However, their use has been stigmatized and banned in much of the world due to their potential for abuse and the risks associated with their consumption. In recent years, however, there has been a resurgence of scientific interest in psychedelics, driven by advances in neuroscience and psychopharmacology, as well as evidence of their therapeutic benefits in treating various psychiatric conditions, such as depression, anxiety, post-traumatic stress disorder, addictions and existential disorders related to terminal illness.

More information

The Psychonaut's Guides available in Colombia from Alpha Editorial

By Gabriel García in News

October 25, 2023

Would you like to explore the depths of your mind and discover new ways to heal and grow? If so, you may be interested in the Psychonaut’s Guides collection, a series of books that provide you with practical and scientific information on the use of psychedelics for therapeutic purposes. Psychedelics are substances that alter perception, thought and mood, and can facilitate experiences of self-awareness, creativity and spiritual connection. Examples include LSD, psilocybin, ayahuasca, peyote and DMT.

More information

Roland Griffiths, one of the world's leading experts on psychedelics and mental health, passed away.

By Gabriel García in News

October 19, 2023

On October 15, Roland Griffiths, psychopharmacologist and researcher on psychedelics and their applications in mental health, left us. Griffiths was one of the pioneers in reactivating the scientific study of substances such as psilocybin, LSD or DMT, after decades of prohibition and stigma. Griffiths graduated in psychology from the University of Wisconsin-Madison in 1972 and obtained his PhD in psychopharmacology from the University of Minnesota in 1976. Since then, he worked as a professor and researcher in the Department of Psychiatry and Neurosciences at Johns Hopkins University, where he founded and directed the Center for Research on Psychedelics and Consciousness.

More information

Harvard launches new Study of Psychedelics in Society and Culture

By Gabriel García in News

October 9, 2023

Harvard University, one of the world’s most prestigious academic institutions, has announced the creation of a new study on psychedelics in society and culture, thanks to a $16 million grant from the Gracias Family Foundation. The study, an interdisciplinary effort involving Harvard’s Faculty of Arts and Sciences, Law School, and Divinity School, aims to “transform the landscape of research on psychedelics by producing cutting-edge scholarship and convening faculty, students, and experts to engage in debate about their broad implications.

More information

How does Ibogaine affect your brain and how it may help to overcome addictions

By Gabriel García in News

September 26, 2023

Ibogaine is a natural substance found in several plant species, especially those of the Apocynaceae family. It is a hallucinogen that has therapeutic properties for the treatment of psychological addiction, that is, the compulsive desire to consume drugs or other substances that generate dependence. What is addiction? Addiction is a disease that affects both the body and the mind. Excessive and prolonged drug use alters the structure and functioning of the brain, causing changes in behaviors, emotions and perception of reality.

More information

MEO-DMT: HOW ITS EFFECTS ON THE BRAIN WORK, WHAT ARE THE RISKS OF ITS USE AND HOW ITS USE AND POTENTIAL BENEFITS ARE BEING RESEARCHED

By Gabriel García in News

September 17, 2023

MeO-DMT, or methoxy-dimethyltryptamine, is a psychoactive substance belonging to the tryptamine group, molecules that have neuromodulatory effects on the brain. MeO-DMT is found naturally in some plants, such as Anadenanthera peregrina or Acacia maidenii, and can also be synthesized in laboratories. Its consumption produces intense hallucinogenic effects, which can last between 5 and 30 minutes, depending on the route of administration. What happens when you consume MeO-DMT MeO-DMT’s effects on the brain are due to its ability to bind to serotonin receptors, a neurotransmitter that regulates mood, perception, sleep and cognition.

More information

Portugal decriminalizes synthetic drug use: what does this imply for medical and scientific research on psychedelics?

By Gabriel García in News

September 6, 2023

On August 31, the Portuguese government announced a historic measure: the decriminalization of the consumption of synthetic drugs, including psychedelic substances such as LSD, MDMA or ketamine. This decision is in addition to the one taken by the country in 2001, when it stopped considering drug use as a crime and treated it as a public health problem. The measure has been applauded by many sectors that defend the therapeutic and scientific use of psychedelics, which have been researching their potential benefits for mental health for decades.

More information

WHAT HAPPENS IF YOU CONSUME MESCALINE? CAN PEYOTE BE USED FOR MEDICAL TREATMENTS?

By Gabriel García in News

August 30, 2023

Mescaline is a psychedelic substance found in some cacti, such as peyote and San Pedro, and has been used since ancient times by various indigenous cultures for religious, ritual and therapeutic purposes. But how does mescaline act in the human brain and what effects does it produce? What potential does this molecule have for the treatment of some mental disorders? In this article we will try to answer these questions based on the available scientific evidence.

More information

What happens in your brain when you have a psychedelic trip?

By Gabriel García in News

August 23, 2023

Psychedelic trips are experiences that alter consciousness and perception of reality, caused by the consumption of substances such as LSD, psilocybin, mescaline or DMT. These drugs act on serotonin receptors in the brain, producing effects such as hallucinations, synesthesia, temporal distortion and ego-dissolution. Ego dissolution is a feeling of losing the boundaries between oneself and the environment, of merging with the universe and transcending individuality. It has been compared to mystical or spiritual experiences described by some religious or cultural traditions.

More information

Who is Christian Angermayer: 100 millions invested in psychedelics

By Gabriel García in News

August 17, 2023

The Forbes article tells the story of Christian Angermayer, a German investor who has bet on psychedelic research as a way to improve people’s mental health and well-being. Angermayer became interested in these compounds after reading a book about the traditional use of sacred plants in different cultures, and decided to try LSD in a session guided by a therapist. The experience changed his life and made him see the therapeutic potential of these substances, which can help treat problems such as depression, anxiety, post-traumatic stress or addictions.

More information

AUSTRALIA REGULATES PSYCHEDELICS AS MEDICINE DRUGS

By Gabriel García in News

Australia has become the first country to classify psychedelic substances as drugs at the national level, opening the door to their therapeutic use to treat various mental health conditions. A France 24 article explains the details of this landmark decision and the implications it has for the future of psychiatry and research. According to the article, Australia’s Therapeutic Goods Administration (TGA) has approved Mind Medicine Australia’s application to reclassify psilocybin and MDMA from Schedule 9 (banned substances) to Schedule 8 (controlled substances).

More information

AUSTRALIA REGULATES PSYCHEDELICS AS MEDICINE DRUGS

By Gabriel García in News

Australia has become the first country to classify psychedelic substances as drugs at the national level, opening the door to their therapeutic use to treat various mental health conditions. A France 24 article explains the details of this landmark decision and the implications it has for the future of psychiatry and research. According to the article, Australia’s Therapeutic Goods Administration (TGA) has approved Mind Medicine Australia’s application to reclassify psilocybin and MDMA from Schedule 9 (banned substances) to Schedule 8 (controlled substances).

More information

Minneapolis Mayor to Loosen Enforcement of Psychedelics

By Gabriel García in News

What do the mayor of Minneapolis, a group of war veterans and an Amazonian tribe have in common? They have all experienced the benefits of psychedelics in improving their mental health, well-being and connection to nature. Psychedelics are substances that alter perception, thought and consciousness, producing profound and revelatory experiences that can change people’s lives. For decades, these substances have been banned and stigmatised by the authorities, but in recent years they have made a strong comeback thanks to scientific research and social activism.

More information

Psychonaut Guides now available in the United Kingdom

By Gabriel García in News

We are very pleased to announce that the Psychonaut Guides books, a series of books exploring the world of psychedelic substances and their therapeutic, cultural and clinical uses, are now available in the UK through Gazelle Book Services. The Psychonaut Guides books are the result of years of research and experience by a multidisciplinary team of authors, including psychologists, pharmacologists and neuroscientists. Each book focuses onpsychedelics substance or family of substances, such as LSD, psilocybin, DMT or ayahuasca, and provides detailed information on their history, pharmacology, effects, risks, benefits and therapeutic potential.

More information

The UN publishes its first report on psychedelics, with the participation of one of our authors.

By Gabriel García in News

Psychedelics are substances that alter perception, mood and thought, and have been used since ancient times for ritual, therapeutic and recreational purposes. However, their use has been restricted and stigmatized by the prohibitionist policies imposed from the 1960s onwards, which also hindered their scientific research. In recent years, there has been a revival of interest in psychedelics, both from academia and from the social and political spheres. There is growing evidence that these substances may have mental health benefits, especially for treating disorders such as depression, anxiety, post-traumatic stress disorder or addiction.

More information

what role is 'maps' playing in the world of psychedelics?

By Gabriel García in News

Psychedelics are substances that alter perception, mood and cognition, and may have therapeutic effects for various mental health conditions, such as post-traumatic stress disorder (PTSD), depression, anxiety, addiction and palliative care. However, for decades, these substances have been stigmatized, banned and marginalized by anti-drug policy and lack of scientific research. In this context, an organization has emerged that aims to change this situation and promote the medical, legal and cultural use of psychedelics: the Multidisciplinary Association for Psychedelic Studies (MAPS).

More information

Psychedelic Science 2023 is here and Psychonaut Guides will participate in the event

By Gabriel García in News

The Psychedelic Science 2023 event, organized by the Multidisciplinary Association for Psychedelic Studies (MAPS) and the Beckley Foundation, will be held in Denver from June 19-23, 2023. It is an international meeting that will bring together leading experts and researchers in the field of psychedelic substances and their therapeutic, spiritual and cultural use. In addition to informative talks, there will be valuable workshops, fun events and market opportunities for those interested in the world of psychedelics.

More information

Nevada Senate Approves Bill to Study Psychedelics and Establish a Working Group for Therapeutic Access

By Gabriel García in News

The Nevada Senate has taken a significant step towards exploring the potential benefits of psychedelics for therapeutic purposes. In a 16-4 vote, the Senate approved a bill that would establish a working group dedicated to studying psychedelics and developing a plan for regulated access. The bill will now be considered by the Assembly, marking a positive development for advocates of psychedelics reform. Nevada and psychedelics Originally, the legislation proposed to legalize psilocybin and promote research into the psychedelic, while also encouraging studies on MDMA.

More information

Minnesota's progressive drug policies are breaking new ground

By Gabriel García in News

Minnesota’s progressive drug policies are breaking new ground by not only focusing on marijuana but also exploring the therapeutic potential of psychedelics. Among the notable changes is the establishment of a Psychedelic Medicine Task Force, which will advise the state legislature on the legal, medical, and policy aspects associated with the legalization of psychedelic medicine. Psychedelics and ‘The Psychedelic Medicine Task Force’ Psychedelic drugs such as LSD, psilocybin mushrooms, and MDMA (commonly known as ecstasy) have long been stigmatized, but a growing number of states and municipalities in the United States are recognizing their potential benefits and moving towards decriminalization.

More information

OHIO UNIVERSITY GETS DEA PERMIT TO PLANT MAGIC MUSHROOMS

By Gabriel García in News

The Ohio State University has become the first U.S. university to obtain a DEA license to grow psychedelic mushrooms. Psychedelic mushrooms, also known as magic mushrooms, are a group of mushrooms that contain psilocybin, a chemical that can alter the perception, mood and cognition of people who consume them. Psilocybin has been used for centuries by various indigenous cultures for ritual, religious and therapeutic purposes, but has also been subject to prohibition and stigma in many countries due to its potential to cause adverse effects and dependence.

More information

SAM ALTMAN, THE EXECUTIVE BEHIND CHATGPT, IS BETTING ON A REVOLUTION IN PSYCHEDELICS.

By Gabriel García in News

Sam Altman is the executive director of OpenAI, the organization that created ChatGPT, the artificial intelligence chatbot that has gone viral for its witty and funny responses. But Altman not only wants to change the way we communicate with machines, but also the way we treat our mental health and our addictions with psychedelic drugs. Altman is the president of a startup called Journey Colab, which aims to harness the potential that psychedelic drugs have shown in clinical trials and make them accessible to people suffering from mental health and substance use disorders.

More information

What is SB 519, or how psychedelics could come to California

By Gabriel García in News

California is one of the most progressive states in the United States in terms of drug policy reform. In recent years, several California cities have decriminalized the use and cultivation of psychedelic plants and mushrooms, including Oakland, Santa Cruz and Berkeley. In addition, there is a state bill that seeks to decriminalize the possession and exchange of small amounts of seven psychedelic substances, including psilocybin, LSD and MDMA, for people over the age of 21.

More information

A postgraduate program on the clinical application of psychedelics has been launched by a UK university

By Gabriel García in News

The University of Exeter in the United Kingdom has announced the launch of a postgraduate course in the clinical use of psychedelics, the first of its kind in Europe. The course, which will begin in September 2023, aims to train mental health professionals in the therapeutic use of substances such as LSD, psilocybin or MDMA, which have been shown to be effective in the treatment of disorders such as depression, post-traumatic stress disorder or addiction.

More information

COULD PSYCHEDELICS HELP TREAT PERSISTENT COVID?

By Gabriel García in News

Yesterday, April 17, 2023, Time magazine published an article entitled “Could Psychedelics Help Treat Long COVID?”. This article explores the possibility that hallucinogenic substances such as LSD, psilocybin or ketamine may alleviate the lingering symptoms suffered by some patients who have recovered from coronavirus. What do we know about this? Can psychedelic drugs help treat long COVID? The article begins with the story of a woman named Sarah, who contracted COVID-19 in March 2020 and has since experienced chronic fatigue, muscle pain, memory loss, and depression.

More information

What are the risks of psychedelic drug use?

By Gabriel García in News

Psychedelic drugs have become a topic of increased interest in recent years due to their potential therapeutic benefits in treating a range of mental health conditions. However, as with any drug, there are risks involved in their use. In this article, we will explore the risks of psychedelic drugs and the safety considerations that should be taken into account. As Anton Gomez-Escolar tells us in the Essential Guide to the Psychedelic Renaissance, the risks of psychedelic drugs depend on various variables.

More information

First map showing how psychedelics affect the brain published

By Gabriel García in News

Psychedelics are substances that alter perception, mood and cognition by acting on different neurotransmitter systems in the brain. Some of the best known psychedelics are LSD, psilocybin (present in magic mushrooms), DMT (present in ayahuasca) and mescaline (present in peyote). These substances can induce intense and immersive experiences, sometimes described as visions, trips or altered states of consciousness. The effects of psychedelics on the brain have been the subject of study for decades, but many aspects are still unknown or difficult to measure.

More information

Oregon first licensed psychedelic guides

By Gabriel García in News

Psychedelic mushrooms are a substance that has generated a lot of interest in recent years for their potential therapeutic benefits in treating various mental health conditions. In this article, we tell you how Oregon has become the first state in the United States to legalize the use of psilocybin, the active ingredient in these mushrooms, and what this breakthrough means for science and society. What is psilocybin and how does it work?

More information

PSYCHEDELICS AND ADDICTIONS: WHAT SCIENCE KNOWS TODAY

By Gabriel García in News, Information

Addiction is a serious public health problem that causes the loss of millions of disability-adjusted life years each year. Although conventional addiction treatments, such as behavioral therapy and psychotropic drugs, are available, their effectiveness is often limited and they carry numerous side effects and health risks. This has led researchers to explore alternative treatments, such as psychedelic-assisted psychotherapy. According to the book Essential Guide to the Psychedelic Renaissance by Antón Gomez-Escolar, several psychedelic substances are being studied for their potential to treat addiction, such as psilocybin, ibogaine, MDMA, DMT and LSD.

More information

Meet: David Nichols

By Gabriel García in News

Source of the original text: https://pharmacy.unc.edu/directory/denichol/ Take a look at our social networks to keep updated: ⇦ Back David Earl Nichols is an American pharmacologist and medicinal chemist. Formerly the Robert C. and Charlotte P. Anderson Chair of Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969.

More information

Ketamine: A Synthetic Substance With Many Applications

By Gabriel García in News, Information

All the information in this article has been taken from the Essential Guide to the Psychedelic Renaissance, now available on Amazon. Ketamine in modern medicine Consumption and dosage of Ketamine Take a look at our social networks to keep updated: ⇦ Back All the information in this article has been taken from the Essential Guide to the Psychedelic Renaissance, now available on Amazon.

More information

The therapeutic potential of psychedelic medicine for elderly population

By Gabriel García in News

February 22, 2023

The American Association on Aging has published an article examining the therapeutic potential of psychedelics for the aging population. According to the World Health Organization, mental disorders are common among older adults and affect approximately 15% of those over the age of 60. The National Council on Aging reports that 80% of adults over the age of 65 suffer from at least one chronic illness, while 68% suffer from two or more, which can exacerbate mental health problems.

More information

Meet: Bill Richards

By Gabriel García in News

February 14, 2023

Original text: https://hopkinspsychedelic.org/richards Take a look at our social networks to keep updated: ⇦ Back William A. Richards, also known as Bill Richards, is a psychologist in the Department of Psychiatry at the Johns Hopkins University School of Medicine, Bayview Medical Center, a consultant/trainer at psychedelic research centers internationally, a professor in the Psychedelic Therapy and Research Program at the California Institute of Integral Studies, and also a clinician in private practice in Baltimore.

More information

Australia approves the use of psilocybin and MDMA for the treatment of mental illnesses

By Gabriel García in News

February 6, 2023

As of July 1, Australia is preparing for a significant change in the way mental illness will be addressed. The Therapeutic Goods Administration (TGA) has given its approval to allow drugs containing psychedelic substances such as psilocybin, found in hallucinogenic mushrooms, and MDMA, commonly known as ecstasy, to be prescribed by licensed psychiatrists. The use of MDMA will be allowed to treat post-traumatic stress syndrome, while psilocybin will be allowed for depression if other therapeutic approaches fail to achieve improvement.

More information

New study on psilocybin use and its effects on bipolar disorder

By Gabriel García in News

January 26, 2023

A new research article in the Journal of Psychopharmacology provides information on the psychological effects of psilocybin in people with bipolar disorder. The results show that although many of these individuals found psilocybin use beneficial, others experienced negative side effects, such as manic symptoms. The use of psilocybin as a therapy for depression is becoming increasingly popular due to its positive results in recent studies. As developed in the Psychonaut’s Guide collection, there is growing evidence that, when used in conjunction with supportive therapy, the ingestion of certain psychedelic compounds can improve the mental health of individuals with various mental disorders.

More information

Virtual Reality on psychedelic therapies?

By Gabriel García in News

January 19, 2023

Virtual reality (VR) is an emerging technology that is increasingly being used in a variety of fields, from entertainment to, more recently, medicine. Within the medical field, in recent years, there has been a growing interest in using VR to recreate experiences with psychedelics, with the aim of investigating their therapeutic effects and improving the understanding of how these substances affect the brain and human behavior as a substitute for the original substances.

More information

Meet: Rick Doblin

By Gabriel García in News

December 21, 2022

Original text source: https://maps.org/people/rick-doblin/ Take a look at our social networks to keep updated: ⇦ Back Born in 1953, Doblin grew up in a conservative Jewish family in the Chicago suburbs. He is the first of four children of pediatrician Morton Doblin and schoolteacher Arline Doblin. He has three younger siblings, Bruce, Sharon and Stuart Doblin.

More information

Germany funds psilocybin study with €2.6m

By Gabriel García in News

December 14, 2022

Germany’s Federal Ministry of Education and Research (BMBF) has granted €2.6m to a study investigating the potential effectiveness of psilocybin as an antidepressant treatment for people who cannot tolerate conventional treatments. The “Efficacy and safety of Psilocybin in treatment-resistant major depression” (EpisoDE) study was launched by the Central Institute for Mental Health (CIMH) Mannheim in 2021. The purpose of this study is to determine whether psilocybin is an effective treatment for people with severe depression.

More information

'DMN' or how psychedelics can help with mental disorders

By Gabriel García in News

December 7, 2022

How can psychedelics help with mental disorders? For that we should first ask ourselves what mental disorders consist of. Simplistically, we could say that when there is a disconnect between our higher models of the world and reality, mental disorders such as depression and addictions occur. Our overactive default network (DMN) filters information in an unhealthy way, controlling how we think, behave and see the world. This limits our ability to relate to situations realistically, reinforcing harmful patterns rather than allowing us to change.

More information

Psychonaut Guides now available in Mexico

By Gabriel García in News

November 30, 2022

Last Thursday the Psychonaut Guides book series was presented in Mexico City, including the three main titles in Spanish: the Essential Guide to the Psychedelic Renaissance, Your brain on psychedelics and Psychedelics and mental health. The Psychonaut’s Guides are updated and scientifically based guides to discover and explore the exciting world of psychedelic substances, their potential and applications that had already made their appearance in Spain. Now, however, this collection aimed at the growing world of psychonauts and the new psychedelic culture, necessary to understand the neuroscience, pharmacology and applications of psychedelics will also be available in Mexico.

More information

Meet: David Nutt

By Gabriel García in News

November 23, 2022

Source: https://www.beckleyfoundation.org/amanda-feilding/ Take a look at our social networks to keep updated: ⇦ Back David Nutt is currently Edmond J. Safra Professor of Neuropsychopharmacology and Director of the Neuropsychopharmacology Unit in the Division of Brain Sciences. After joining Bristol Grammar School, David obtained an open scholarship to Downing College, Cambridge and then completed his medical training at Guy’s Hospital, London, continuing in neurology to MRCP.

More information

Colorado Legalizes Psilocybin Sessions and Individual Use

By Gabriel García in News

November 17, 2022

The state has become the second in the country to pass such a measure, after Oregon did so in 2020. Voters in the U.S. state of Colorado have approved by popular vote a measure to legalize the use and cultivation of several natural psychedelics and psilocybin therapy in licensed facilities. Colorado has thus become the second state in the country to pass such a measure, after Oregon voters succeeded in 2020.

More information

Spain first European country to approve a medicine based on ketamine

By Gabriel García in News

November 8, 2022

Esketamine will be prescribed to at least 30% of patients who do not respond to two conventional treatments. The China Antiviral Treatment Association (JILA) group has announced that the pricing of esketamine nasal spray, registered by Johnson & Johnson under the name “Spravato”, in combination with other antidepressants, reaching an agreement for the marketing of the first ketamine-based drug in Spain and Europe. The aim of this drug is to be used in approximately 30% of cases, since the combination of traditional antidepressants has a limited clinical benefit, as the increasing number of suicides in people with diagnosed depression.

More information

Nearly half of Americans support legalization of psychedelics for mental health, according to a poll

By Gabriel García in News

October 26, 2022

Nearly half of Americans support legalization of psychedelics for mental health, according to a new poll by VeryWellMind 45% of Americans say they support legalization of some legal psychedelic substances for treatment of mental illness, provided that they are supervised by a medical doctor, mental health professional, or other health care provider. The results from this new study on these substances coincide with growing pressure to study the deadly effects of these substances and take steps to protect people from their potentially damaging effects.

More information

Meet: Torsten Passie

By Gabriel García in News

October 17, 2022

Text extracted from: https://psychedelicreview.com/person/torsten-passie/ Take a look at our social networks to keep updated: ⇦ Back Dr. Torsten Passie (born 1961) is a German psychiatrist, professor at the Hannover Medical School and internationally renowned scientific expert on altered states of consciousness. He received his degree in philosophy and sociology from the Leibniz University of Hannover and his doctorate from the Hannover Medical School.

More information

Psychedelic Renaissance: a chronology

By Gabriel García in News

October 10, 2022

The Psychedelic Renaissance is in full swing. Every few weeks we hear in national and international media about new studies, scientific advances and political debates and measures to legalize or decriminalize its use. But when did the clinical use of psychedelics begin to permeate mainstream culture? Was it through the media, or did it come from elsewhere? In this article we are going to analyze it. 1. Psychedelics may be the future The psychedelic revolution is coming.

More information

Meet: Amanda Feilding

By Gabriel García in News

September 29, 2022

Text extracted from: https://www.beckleyfoundation.org/amanda-feilding/ Take a look at our social networks to keep updated: ⇦ Back With this article we open a section in the page, “Meet:“. This section aims to divulge about some of the most important figures within the scientific advancement and the so-called psychedelic renaissance. For this purpose, we have chosen as our first personality to highlight Amand Feilding.

More information

Are we really immersed in a psychedelic renaissance?

By Gabriel García in News

September 22, 2022

The book Essential Guide to the Psychedelic Renaissance by Antón Gómez-Escolar, tells us how in 1938 Albert Hofmann, after having accidentally absorbed an infinitesimal amount of a compound he had just synthesized in his laboratio, returned home experiencing a cognitive sensation out of reality. He had just discovered the effects of LSD. Between this event, celebrated in the psychedelic community as the beginning of all that was to come, and the famous summer of love and counterculture, three decades were to pass.

More information

New study on the effects of LSD on reducing anxiety and depression

By Gabriel García in News

September 15, 2022

A new study published in the journal Biological Psychiatry appears to conclude that psychedelic-assisted therapy may be an effective and long-lasting treatment for symptoms related to anxiety and depression. The results, measured using scientifically validated and widely used questionnaires, appear to have been much better than the researchers expected. To conduct the study, a team of Swiss researchers administered twenty participants diagnosed with a life-threatening illness, and twenty-two other participants with a mental disorder, significant amounts of LSD under the supervision of a trained therapist.

More information

San Francisco decriminalizes psychedelics

By Gabriel García in News

September 8, 2022

A few weeks ago we told you how Portugal became a reference in the legal issue and psychedelics two decades ago, decriminalizing their use. At the end of the article, we wished that the rest of the countries would look at this type of measures and start to expand. Well, this morning we woke up to fantastic news: San Francisco has decriminalized psychedelics. Psychedelics such as psilocybin and ayahuasca will be “among the lowest priorities” for law enforcement.

More information

Are psychedelic substances drugs?

By Gabriel García in News

September 1, 2022

As Antón Gómez-Escolar tells us at the beginning of the second chapter of the Essential Guide to the Psychedelic Renaissance, “psychoactive substances are those that when introduced into the organism by any route (oral, nasal, intramuscular, intravenous) exert a direct effect on the Central Nervous System, causing specific changes to its functions (pain, mood, perceptions, etc), as for example do alcohol, caffeine, anxiolytics, antidepressants, some analgesics,. . and drugs.”

More information

Conference 'From the Psychedelic Renaissance to the Enlightenment'

By Gabriel García in News

August 24, 2022

The Psychedelic Conference: Innovative Approaches in Mental Health: Achievements and Challenges of Psychedelic Assisted Therapy will take place next Saturday, November 19. The meeting, organized by the Psychedelic Association Fuerteventura, will bring together some of the leading voices in psychedelic research, including the Psychedelic Guides book series, official sponsors of the event. The event will include among the speakers the scientific supervisor of the book series, José Carlos Bouso, as well as the author of Tu Cerebro con Psicodélicos, Genís Oña, and the legal advisor of the collection, Francisco Azorín.

More information

Jose Carlos Bouso's new study provides evidence of interaction between the effects of THC and CBD and social cognition skills

By Gabriel García in News

August 17, 2022

Jose Carlos Bouso, scientific director of the Psychonaut Guides book series, has published a new study that aims to determine the effect of THC and CBD on social cognition skills, testing how CBD may counteract the possible effects of THC on these abilities. The hypothesis stated that participants under the effects of THC would show lower social cognition skills, and co-administration of THC-CBD would counteract these effects. In order to prove this, the authors designed a contextual, naturalistic, randomized, double-blind, placebo-controlled, crossover study to test the acute neuropsychological effects of vaporizing different types of cannabis extracts.

More information

What happens in your brain when you consume ayahuasca?

By Gabriel García in News

August 11, 2022

DMT (dimethytriptamine) is a natural psychoactive compound of the hallucinogen class, present in varying amounts in many plants, such as mimosas, acacias, mimosas or chacrunas. Traces of DMT can also be found in some mammalian organisms, although its function in our body is still unknown. DMT belongs to the chemical family of tryptamines and is a very simple compound, very similar to tryptophan (a common amino acid in the diet).

More information

5 legal psychedelic substances you may not have known about

By Gabriel García in News

In our book series Psychonaut Guides we talk in depth about the most commonly used traditional psychedelics, but there are also other psychedelics of less common use and, among them, some are legal under certain circumstances. Here are 5 legal psychedelic substances you may not have known about. 1. HAWAIIAN BABY WOODROSE Hawaiian Baby Woodrose (Argyreia nervosa) is a perennial climbing plant native to India, with large heart-shaped leaves and white stunted flowers.

More information

How does LSD affect your brain?

By Gabriel García in News

LSD stands for lysergic acid diethylamide. It is a psychoactive substance, which means that it acts on the central nervous system. This results in a change in behavior and the way the user relates to the world around them. These effects occur because of the way LSD affects the action of a brain chemical called serotonin. This substance helps control mood, thinking, behavior, and the senses. As Anton Gomez-Escolar tells us in the Essential Guide to the Psychedelic Renaissance, LSD was originally used as a psychotomimetic.

More information

The day Portugal decriminalized psychedelics

By Gabriel García in News

23 years ago Portugal decriminalized the consumption of narcotics. Contrary to what many expected at the time, this measure brought about a reduction in the consumption of substances such as heroin or cocaine, as well as a drop in the rate of HIV patients. Source: Portugal’s Parliament discusses comprehensive regulation of cannabis (https://canamo.net/noticiasimundo/el-parlamento-de-portugal-discute-la-regulacion-integral-del-cannabis) After the end of the dictatorship, a countercultural movement swept Portugal. And, as with much of the countercultural movements in the West after World War II, this wave was accompanied by a boom in the consumption of different types of substances.

More information

Why are Set and Setting important when taking psychedelic substances?

By Gabriel García in News

We usually talk about the potential positive effects of psychedelic substances, however, it is important to keep in mind that these potential positive effects of psychedelic substances usually have an important psychological burden. That is why the psychological variables of person and context are especially crucial to not only make this type of experience as risk-free as possible, but also to turn it into a positive and, hopefully, transcendental experience.

More information

What effects does psilocybin have on your brain?

By Gabriel García in News

As Antón Gómez-Escolar tells us in his Essential Guide to the Psychedelic Renaissance, throughout history, psilocybin mushrooms have had various religious, ritual and shamanistic uses. Nowadays, its use can be associated with recreational, spiritual, self-knowledge contexts and, therapeutically, it is investigated for the treatment of depression, anxiety, post-traumatic stress disorder, addictions or obsessive-compulsive disorder. But, how exactly does psilocybin act in our brain?? Antón Gómez-Escolar answers this question in his book, from which the information in this article is taken.

More information

Three psychedelic substances for legal use

By Gabriel García in News

We recently heard the news of the release of the first trailer for Netflix’s new four-part documentary series ‘How to Change Your Mind’, based on Michael Pollan’s best-seller. With the mainstream world every day more immersed in the Psychedelic Renaissance, and awaiting regularization and legalization of the therapeutic use of these substances, in this post we have collected three legal psychedelic substances, with information about them extracted from the Essential Guide to the Psychedelic Renaissance, by Antón Gómez-Escolar, indicating in which countries and under what circumstances they are legal:

More information

MICHAEL POLLAN'S 'HOW TO CHANGE YOUR MIND' ARRIVES ON NETFLIX

By Gabriel García in News

The first trailer for Netflix’s new four-part documentary series How to Change Your Mind has been released. New York Times best-selling author Michael Pollan’s 2018 book How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence is being adapted by Academy Award winner Alex Gibney. The documentary series, like the book, aims to inform viewers about a lesser-known side effect of some psychedelic drugs.

More information

Why is the use of some psychedelics illegal?

By Gabriel García in News

The idea of banning all “recreational” use of certain psychoactive substances was driven by a growing influence of Anglo-American Christian Puritanism and the temperance movement against alcohol in the late temperance movement against alcohol in the late nineteenth and early twentieth centuries, which in the United States also led to the prohibition of alcohol in the United States between 1920 and 1933. The campaign for prohibition was also fueled by racist sentiments toward by racist sentiments toward immigrants from China and Mexico, who used opiates and cannabis.

More information

Why are psychedelics making a comeback?

By Gabriel García in News

According to the World Health Organization (WHO), around the world there are 450 million people suffering from mental disorders and estimates that one in four people in the world will suffer, at some point in their lives, some mental disorder. Faced with this panorama and the lack of success in the treatment of some of the diseases, several researchers have resorted to look for other alternatives, among them, the use of psychedelics.

More information

What are psychedelics? Psychedelics and Mental Health

By Gabriel García in News

The Psychedelic Renaissance promises to revolutionize mental health through the use of psychedelics, but what exactly are psychedelics? The relationship between psychedelics and mental health has been studied since the 1940s. As we discussed in our post on the Psychedelic Renaissance, the excess of uncontrolled recreational use and a campaign to discredit the cultural movement to which they were linked caused research on their effects on mental health to be abandoned in most universities.

More information

Your Brain on Psychedelics: How do psychedelics work?

By Gabriel García in News

Pharmacology and neuroscience of psilocybin, DMT, LSD, MDMA or mescaline. “When I first approached psychedelic drugs, I knew instantly that my life was changed.” So begins Your Brain with Psychedelics, by Genís Oña, psychologist and pharmacologist and researcher at ICEERS (International Center for Ethnobotanical Education, Research, and Service). That change in his life, as a transcendental before and after, is one of the multiple themes explored in Your Brain with Psychedelics.

More information

The Psychedelic Renaissance, a guide to an essential movement

By Gabriel García in News

The Psychonaut Guides are now available in Amazon and Apple Books. The Essential Guide to the Psychedelic Renaissance, the first title that opens the book series, will introduce us to the exciting world of psychedelics by the hand of Antón Gómez-Escolar. This title is ideal whether you are approaching the Psychedelic Renaissance movement for the first time or you are passionate about this world, as it brings together the history, neuroscience, legality, therapeutic applications and harm reduction methods of the most promising psychedelic drugs for science.

More information

First three PsychonautGuides.com books available now

By Gabriel García in News

The first books of PsychonautGuides.com have been released. Psychonaut Guides launches a series of books with a scientific approach for those who want to explore and discover the exciting world of hallucinogens, their potential and applications as part of the so-called Psychedelic Renaissance. Opening this collection on the Psychedelic Renaissance, we have the book by Antón Gómez-Escolar, “Essential Guide to the Psychedelic Renaissance”, which presents the history, neuroscience, legality, therapeutic applications and harm reduction of the most promising psychedelic drugs for science, as an introduction to this revolution that is beginning to spread around the world.

More information

Book series presentation in New York and Boston

By Gabriel García in News

In the last few days two presentations of the first three books that will open the Psychonaut Guides collection have taken place in the United States. The first presentation in the United States has taken place in Boston and the second one in New York. Both events had an excellent reception among the participants, who were able to obtain some copies of the books, as you can start to see in the social networks, and have an interactive talk about the psychedelic world.

More information

First PsychonautGuides.com titles to be released soon

By Gabriel García in News

In the coming weeks the first three books of the PsychonautGuides.com catalogue will be available. The launch will be made in conjunction with the PsychonautGuides.com website and the titles will be available in English and Spanish, as well as in full color or B&W versions. Digital versions of the books will available in Amazon, Google Books and many other selling channels. The first introductory book to the collection will be “Essential Guide to the Psychedelic Renaissance”, by Antón Gómez-Escolar.

More information

Copyright © 2022 Argonowta; all rights reserved.

Template by Bootstrapious. Ported to Hugo by DevCows.